These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 21074634)

  • 61. Implementation of an ADME enabling selection and visualization tool for drug discovery.
    Stoner CL; Gifford E; Stankovic C; Lepsy CS; Brodfuehrer J; Prasad JV; Surendran N
    J Pharm Sci; 2004 May; 93(5):1131-41. PubMed ID: 15067690
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The influence of lipophilicity in drug discovery and design.
    Arnott JA; Planey SL
    Expert Opin Drug Discov; 2012 Oct; 7(10):863-75. PubMed ID: 22992175
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Lipophilicity and hydrophobicity considerations in bio-enabling oral formulations approaches - a PEARRL review.
    Ditzinger F; Price DJ; Ilie AR; Köhl NJ; Jankovic S; Tsakiridou G; Aleandri S; Kalantzi L; Holm R; Nair A; Saal C; Griffin B; Kuentz M
    J Pharm Pharmacol; 2019 Apr; 71(4):464-482. PubMed ID: 30070363
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Drug targeting via retrometabolic approaches.
    Bodor N; Buchwald P
    Pharmacol Ther; 1997; 76(1-3):1-27. PubMed ID: 9535166
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits.
    Wunberg T; Hendrix M; Hillisch A; Lobell M; Meier H; Schmeck C; Wild H; Hinzen B
    Drug Discov Today; 2006 Feb; 11(3-4):175-80. PubMed ID: 16533716
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties?
    Giordanetto F; Kihlberg J
    J Med Chem; 2014 Jan; 57(2):278-95. PubMed ID: 24044773
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Modeling of activity landscapes for drug discovery.
    Bajorath J
    Expert Opin Drug Discov; 2012 Jun; 7(6):463-73. PubMed ID: 22475223
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Characteristic physical properties and structural fragments of marketed oral drugs.
    Vieth M; Siegel MG; Higgs RE; Watson IA; Robertson DH; Savin KA; Durst GL; Hipskind PA
    J Med Chem; 2004 Jan; 47(1):224-32. PubMed ID: 14695836
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Chemistry challenges in lead optimization: silicon isosteres in drug discovery.
    Showell GA; Mills JS
    Drug Discov Today; 2003 Jun; 8(12):551-6. PubMed ID: 12821303
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Organic chemistry in drug discovery.
    MacCoss M; Baillie TA
    Science; 2004 Mar; 303(5665):1810-3. PubMed ID: 15031494
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Industrial medicinal chemistry insights: neuroscience hit generation at Janssen.
    Tresadern G; Rombouts FJR; Oehlrich D; Macdonald G; Trabanco AA
    Drug Discov Today; 2017 Oct; 22(10):1478-1488. PubMed ID: 28669605
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Refining the chemical toolbox to be fit for educational and practical purpose for drug discovery in the 21st Century.
    Lolli M; Narramore S; Fishwick CW; Pors K
    Drug Discov Today; 2015 Aug; 20(8):1018-26. PubMed ID: 25959506
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Should medicinal chemists do molecular modelling?
    Ritchie TJ; McLay IM
    Drug Discov Today; 2012 Jun; 17(11-12):534-7. PubMed ID: 22269135
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space.
    Meanwell NA
    Chem Res Toxicol; 2016 Apr; 29(4):564-616. PubMed ID: 26974882
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Do medicinal chemists learn from activity cliffs? A systematic evaluation of cliff progression in evolving compound data sets.
    Dimova D; Heikamp K; Stumpfe D; Bajorath J
    J Med Chem; 2013 Apr; 56(8):3339-45. PubMed ID: 23527828
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Compound aggregation in drug discovery: implementing a practical NMR assay for medicinal chemists.
    LaPlante SR; Carson R; Gillard J; Aubry N; Coulombe R; Bordeleau S; Bonneau P; Little M; O'Meara J; Beaulieu PL
    J Med Chem; 2013 Jun; 56(12):5142-50. PubMed ID: 23730910
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The influence of drug-like concepts on decision-making in medicinal chemistry.
    Leeson PD; Springthorpe B
    Nat Rev Drug Discov; 2007 Nov; 6(11):881-90. PubMed ID: 17971784
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Transforming fragments into candidates: small becomes big in medicinal chemistry.
    de Kloe GE; Bailey D; Leurs R; de Esch IJ
    Drug Discov Today; 2009 Jul; 14(13-14):630-46. PubMed ID: 19443265
    [TBL] [Abstract][Full Text] [Related]  

  • 79. ROCK: the Roche medicinal chemistry knowledge application - design, use and impact.
    Mayweg A; Hofer U; Schnider P; Agnetti F; Galley G; Mattei P; Lucas M; Boehm HJ
    Drug Discov Today; 2011 Aug; 16(15-16):691-6. PubMed ID: 21439402
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Medicinal chemistry in drug discovery in big pharma: past, present and future.
    Campbell IB; Macdonald SJF; Procopiou PA
    Drug Discov Today; 2018 Feb; 23(2):219-234. PubMed ID: 29031621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.